347151-53-5

Basic information

• Product Name: 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester
• Synonyms: 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester
• CAS NO: 347151-53-5
• Molecular Weight: 416.433
• Mol File: 347151-53-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester(347151-53-5)
• EPA Substance Registry System: 4-(6,7-Dimethoxyquinolin-4-yloxy)phenylcarbamic acid phenyl ester(347151-53-5)

Safety Data

• Hazardous Substances Data: 347151-53-5(Hazardous Substances Data)

Upstream product

• 190728-25-7 4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 108-95-2 phenol 
• 35654-56-9 6,7-dimethoxy-4-chloroquinoline 
• 26717-39-5 [[(3,4-Dimethoxyphenyl)amino]methylene]malonic acid,diethyl ester 
• 123-30-8 4-amino-phenol 
• 1131-62-0 1-(3,4-dimethoxyphenyl)ethanone 
• 190728-24-6 6,7?dimethoxy?4?(4?nitrophenoxy)quinoline 
• 13425-93-9 6,7-dimethoxyquinoline-4-ol 
• 4101-32-0 4',5'-dimethoxy-2'-nitroacetophenone 
• 1885-14-9 phenyl chloroformate 
• 144-55-8 sodium hydrogencarbonate 
• 26893-22-1 1,4-Dihydro-6,7-dimethoxy-4-oxo-3-quinolinecarboxylic acid 
• 127285-54-5 1,4-dihydro-6,7-dimethoxy-4-oxoquinoline 

Downstream Products

• 417719-53-0 N-Cyclopropyl-N'-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)urea 
• 417719-52-9 N-(thiazol-2-yl)-N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)urea 

Relevant articles and documents

Identification of potent and selective inhibitors of PDGF receptor autophosphorylation

We report the structure-activity relationship of quinoline and quinazoline derivatives, which include urea, thiourea, urethane, and acylthiourea groups, as inhibitors of the platelet-derived growth factor (PDGF) receptor autophosphorylation. Our previous studies showed that the quinoline and quinazoline derivatives including urea, thiourea, and carbamate groups were highly potent compounds as the PDGF receptor autophosphorylation inhibitor, but these compounds did not exhibit receptor selectivity between the PDGF receptor and the c-kit receptor. As a result of further synthesis and biological evaluation, we have found that the quinoline and quinazoline-acylthiourea derivatives showed not only good inhibitory activity for the PDGF receptor but also receptor selectivity between the PDGF receptor and the c-kit receptor. Furthermore N-{4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N′-(2- methylbenzoyl)thiourea exhibited potent oral efficacy in in vivo assay using the rat carotid balloon injury model. Therefore, the quinoline and quinazoline-acylthiourea derivatives may be expected to have potential as therapeutic agents for the treatment of restenosis.

Design, synthesis, and biological evaluation of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives as FLT3 inhibitors for the treatment of acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) was an important therapeutic target in acute myeloid leukemia (AML). We synthesized two series of 4-((6,7-dimethoxyquinoline-4-yl)oxy)aniline derivatives possessing the semicarbazide moiety and 2,2,2-trifluoro-N,N′-dimeth

QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME

There are provided compounds which can be used in the treatment of diseases mediated by the autophosphorylation of a PDGF receptor, specifically, compounds which can inhibit neointima formation hypertrophy. The compounds are those represented by formula (